ROIV – roivant sciences ltd. (US:NASDAQ)
Stock Stats
News
Vivek Ramaswamy turns to conservative youth to shape the movement's next phase, analyzes 2026 races [FOX News]
Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at Guggenheim.
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? [Yahoo! Finance]
Immunovant (IMVT) Is Up 14.0% After Roivant-Backed $550 Million Equity Raise For IMVT-1402 - Has The Bull Case Changed? [Yahoo! Finance]
Roivant Sciences (NASDAQ:ROIV) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $24.00 to $33.00. They now have a "buy" rating on the stock.
Form 4 Roivant Sciences Ltd. For: Dec 20 Filed by: Pulik Richard
Form 144 Roivant Sciences Ltd. Filed by: Pulik Richard
Form 144 Roivant Sciences Ltd. Filed by: Pulik Richard
Form 144 Roivant Sciences Ltd. Filed by: Venker Eric
Form 4 Roivant Sciences Ltd. For: Dec 17 Filed by: Sukhatme Mayukh
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.